BioNTech Launches Legal Challenge in mRNA Vaccine Patent Dispute

BioNTech files patent lawsuit against Moderna while shifting focus to oncology. The firm reports strong cash reserves and upgraded revenue guidance ahead of its 2025 results.

As investors await the company's upcoming financial report, BioNTech has initiated a significant legal offensive against its primary competitor. The German biotech firm, headquartered in Mainz, has filed a patent infringement lawsuit against U.S.-based rival Moderna. This legal maneuver underscores a high-stakes battle for technological leadership and market share in the still-lucrative mRNA sector, extending beyond mere principle.

Financial Fortitude Ahead of Key Report

All eyes are on BioNTech's fundamental performance ahead of a pivotal disclosure. The company is scheduled to release its fourth-quarter and full-year 2025 results on March 10, 2026. It approaches this date from a position of considerable strength, holding cash and securities reserves of approximately €17.2 billion as of the end of 2025.

Operational performance has also surpassed initial expectations. Management raised its 2025 revenue forecast to a range of €2.6 billion to €2.8 billion. This substantial war chest is viewed as critical for funding the company's costly strategic transformation.

Strategic Shift Toward Oncology Focus

The core of BioNTech's long-term strategy is now firmly centered on cancer treatments. The company aims to have a total of 15 Phase 3 clinical trials underway by the end of 2026. Data readouts from seven late-stage studies are anticipated this year alone. Presently, more than 25 drug candidates are in Phase 2 or Phase 3 development, including promising therapies targeting lung and breast cancer.

Market experts hold mixed views on this strategic pivot. In January, Goldman Sachs upgraded its rating on the stock. Conversely, Leerink Partners adopted a more cautious stance in February, downgrading its recommendation following a recent share price recovery. The equity currently trades near €94, struggling for clear direction after declining roughly 11% over the past year.

The March 10 report represents a crucial test for the leadership. Investors will require not only solid financial figures but, more importantly, evidence of tangible progress within the densely populated oncology pipeline to justify the current valuation sustainably.

Escalating Legal Battle Over mRNA Technology

The legal conflict between the two vaccine pioneers has intensified. On February 19, BioNTech submitted its complaint to a federal court in Delaware. The lawsuit alleges that Moderna's next-generation COVID-19 vaccine, mNEXSPIKE, infringes upon patents held by the German company. The dispute specifically involves an mRNA vaccine design that enables administration at lower doses—a technology advanced by BioNTech and partner Pfizer during the development of Comirnaty.

The outcome carries significant consequences for Moderna. The challenged mNEXSPIKE vaccine is projected to account for about 55% of the U.S. firm's COVID-related revenue during the 2025/2026 season. A Moderna spokesperson has stated the company will vigorously defend against the claims. This legal action also serves as a countermove to prior disputes, as Moderna itself initiated proceedings against BioNTech and Pfizer back in 2022.